LPCN Lipocine Inc
Company Analysis
Latest News
🔴 Lipocine is trading 8.1% down in pre-market; catalyst remains unclear
Lipocine is trading at $2.10 (-8.10%) in pre-market, with the catalyst remaining unclear. - No reliable September 2, 2026 company-specific announcement,...
🟢 Lipocine is trading 5% up today as biotech sector rallies
Lipocine is trading at $2.26 (+5.12%) on August 27, 2026, alongside a strong biotech-sector rally. - The SPDR S&P Biotech ETF (XBI) was reported up 2.06%,...
🟢 Lipocine is trading 5.35% up today on broader biotech strength
Lipocine is trading 5.35% up at $2.27, supported mainly by broader biotech-sector strength. - Biotech ETF XBI is up 2.06% during the regular session,...
🟢 Lipocine is trading 6.8% up today in pre-market amid possible broader risk-on sentiment
Lipocine is trading 6.8% up at $2.20 after closing at $2.06 on August 24, 2026, possibly reflecting broader risk-on sentiment. - No August 25 company-specific...
🟢 Lipocine is trading 5.83% up today with no clear company-specific catalyst
Lipocine is trading 5.83% up now at $2.18, with no clear company-specific catalyst identified for August 14, 2026. - The latest identified corporate...
🟢 Lipocine is trading 8% up today as softer rate-hike expectations support equities
Lipocine is trading at $2.22, up 7.95% on August 13, 2026, as broader risk appetite supports equities after softer rate-hike expectations following CPI. - The...
Lipocine's second quarter net loss widens to $2.6M as it plans a new trial for its PPD drug after a Phase 3 failure.
Lipocine reported a second quarter net loss of $2.6 million, or ($0.32) per share, compared to a net loss of $2.2 million, or ($0.41) per share, in the prior...
🟢 Lipocine is trading 6.13% up today following Q2 results and board appointment
Lipocine is trading at $2.26 (+6.13%) after reporting second-quarter 2026 results and announcing a key addition to its board of directors. • The company...
Lipocine Revenue Plummets as Postpartum Drug Fails, FDA Meeting Looms
Lipocine reported second-quarter 2026 revenue of $190,099. This represents a sharp decline from $622,849 in the prior-year period. The drop resulted from the...